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Comorbidity
Bipolar disorderA 19-year-old woman with a medical history of depressive mood arrived and was treated with lamotrigine at
25 mg/day. On day 10, a high fever of 39.3°C and a diffuse, erythematous, pruritic full-body rash involving the
palms of her hands and the soles of her feet developed, and she was diagnosed with Stevens-Johnson
syndrome (SJS). On day 17, white blood cell count (WBC) result was 1,240/μl with 54.1% neutrophils (670/μl),
and the WBC decreased to 840/μl with 60.7% neutrophils (510/μl) on day 18. The trend toward improvement
included skin symptoms after steroid pulse therapy using 1000 mg/day. Based on the clinical course, we
concluded that the SJS and leukopenia and/or neutropenia are associated with lamotrigine. Monitoring of
WBC should be kept in mind when administering lamotrigine.+81 172 39 5067.
ui-Furukori).
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Lamotrigine is widely used in the treatment of epilepsy and bipolar
disorders. Although its precise mechanism of action remains
unknown, it is believed to act as an anticonvulsant via an effect on
sodium channels. In vitro pharmacological studies have suggested
that lamotrigine inhibits voltage-sensitive sodium channels, leading
to a stabilization of neuronal membranes and a consequent
modulation of the presynaptic transmitter release of excitatory
amino acids, such as glutamate and aspartate [1]. This pharmacolog-
ical proﬁle may explain the therapeutic effects of this drug on bipolar
disorder [1]. A serious rash was deﬁned as one that required a
hospitalization and included Stevens–Johnson syndrome (SJS) and
toxic epidermal necrolysis (TEN). SJS and TEN are severe, life-
threatening reactions that have been associated with over 100
medications [2,3]. These reactions are characterized by erythema
and tenderness of the skin and mucosa, fever, skin blistering or
crusting, ulceration of the mucous membranes, and subepidermal
separation. SJS is deﬁned as epidermal detachment of less than 10%,
and TEN refers to epidermal detachment that exceeds 30%; transi-
tional SJS–TEN is deﬁned as 10%–30% epidermal detachment.
Mortality rates for SJS and TEN are 5% or less and 25%–30%,
respectively [2,3]. The reported frequency of serious rash in adults
using lamotrigine for adjunct therapy in epilepsy is 0.3% [1]. In clinical
trials of lamotrigine for the treatment of bipolar and other mood
disorders, 0.08% of adults receiving lamotrigine as monotherapy
developed rashes [1]. Most cases occurred within 2 to 8 weeks oftreatment. Numerous case reports have described SJS and TEN in adult
patients receiving lamotrigine for antiepileptic indications [4];
however, reports of these dermatological reactions in patients
receiving lamotrigine for the treatment of bipolar disorder are limited
[5–8]. We encountered a case involving not only SJS but also
leukopenia and/or neutropenia during lamotrigine treatment.
2. Case
A 19-year-old woman with a medical history of atopic dermatitis
arrived at our hospital. She had suffered from a depressive mood for
3 months. Her diagnosiswas bipolar disorder II due toher currentmajor
depressive episode and a previous hypomanic episode. Lamotrigine at
25 mg/day was initiated and increased to 50 mg/day on day 10.
Although themental status of the patient recovered immediately, a high
fever of 39.3°C and a diffuse, erythematous, pruritic full-body rash
involving the palms of her hands and the soles of her feet appeared on
day 13 (Fig. 1B and D). She went to a primary clinic, and the results of
laboratory tests were nearly normal with the exception of her white
blood cell (WBC) count, which was 2400/μl. She took 600 mg/day
ibuprofen and 120 mg/day fexofenadine for 3 days. In addition to rash,
slight bumps also appearedonher lips, spreading toher oralmucosaand
beginning to appearvesicular and crusty (Fig. 1C).However, conjunctiva
or genital mucosa was not involved. Lymphadenopathy, organomegaly,
and eosinophilia were not observed. We suspected a side effect
associated with lamotrigine and discontinued the medication on day
14. On Day 17, because of the SJS and WBC result of 1240/μl with
neutrophils 54.1% of 670/μl, we admitted her to the psychiatric ward
after consultationwith dermatologists. Other laboratory tests, including
aspartate aminotransferase, alanine aminotransferase, gamma-glutamylense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Steroid pulse therapy using 1000-mg/day per drop infusion of
intravenous methylprednisolone injection was administered for
3 days on the same day. A pathological examination revealed that a
high level of apoptosis and a low level of lymphocyte permeation were
observed in the epidermis, with apoptosis and granulation tissue
formation at the dermis/epidermis basal layer (Fig. 2A and B). Her
symptoms and dermatological manifestations revealed a slight
improvement. However, the WBC decreased to 840/μl with neutrophils
60.7% 510/μl on day 18, but recovered to 3170/μl with neutrophils
72.9% 2310/μl on day 19 and increased to 6150/μl with neutrophils 55.5%
3410/μl and 4440/μl with neutrophils 72.4% 3210/μl on day 20 and day
24, respectively. Because the trend toward improvement included
skin symptoms, the steroid dose was gradually decreased from 60 to
30 mg/day on day 27, and she was discharged. Her mental status
remained stable.3. Discussion
The present case demonstrated that SJS and leukopenia and/or
neutropenia developed after lamotrigine administration and recovered
after the discontinuation of lamotrigine. Based on the clinical course, we
concluded that the SJS and leukopenia and/or neutropenia are associated
with lamotrigine, and this is the ﬁrst report to make this assertion.
Though one case series study suggested that comorbidity between SJS
and leukopenia and/or neutropenia is common (56%) [9], another such
study demonstrated that leukopenia was not commonly observed with
SJS, appearing in 2 of 29 cases (6.9%) [10]. Neither of these cases was
associated with lamotrigine. The time course for starting the reaction
and prodromal symptoms, such as fever, in this case was typical.A)
C)
Fig. 1. This clinical photograph shows skin eruptions, erythematous papules and superﬁcial
(A), hands (B) and arm (C) of the patient. Mucosal involvement with mild oral labial ulcerAn antiepileptic drug hypersensitivity syndrome (AHS) is
characterized by fever, internal organ involvement and rash.
Mucous membrane involvement is neither as prominent nor as
severe as in SJS and TEN. Fever and systemic syndrome typically
precede or are coincident with cutaneous eruption. Occasionally,
patients develop a rash ﬁrst and then rapidly develop fever with
other systemic symptoms. Rash usually begins with patchy
macular erythema that may become pruritic and papular, which
was not observed in this case. A review revealed 18 cases before
2004. Among these cases, fever and rash were noted in 100% of
patients. Speciﬁcally, maculopapular rashes were observed, with
elevated transaminase levels and eosinophilia being the next
most common ﬁndings. Neutropenia was observed in only 4
(22%) of the 18 patients suffering from AHS [11]. In addition, no
abnormality was observed in our case with respect to liver
function tests, peripheral lymphadenopathy, eosinophilia or
increased C reactive protein, which represent the constellation
of clinical and laboratory features of AHS [12]. We therefore
concluded that the present case does not follow the typical
symptoms and clinical features of AHS.
The cross-sensitivity rates of skin rash between certain antiepi-
leptic drugs are high, particularly when involving carbamazepine,
phenytoin and lamotrigine [13]. The cross-sensitivity rates from
lamotrigine to carbamazepine are 26.3%, those from lamotrigine to
phenytoin are 38.9%, and those from lamotrigine to oxcarbamazepine
are 20.0%. Therefore, other antiepileptic agents should be avoided in
the case of potential cross-sensitivity reactions.
In conclusion, we encountered a case of comorbidity between
SJS and leukopenia and/or neutropenia during lamotrigine treat-
ment. Monitoring of WBC should be kept in mind when adminis-
tering lamotrigine.B)
D)
erosions in addition to atypical target lesions, which are primarily located on the face
ation and superﬁcial keratoconjunctivitis (D).
A) B)
Fig. 2. The photomicrograph shows the vacuolar change in the basal layer of epidermis, with early separation of the basal layer from the papillary dermis (A). Apoptosis of individual
keratinocytes and granulation under dermis and apoptosis and lymphocytic inﬁltrate in the epidermis are noted (B) (hematoxylin and eosin, ×100).
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